IDEXX Laboratories Analyst Price Targets - Benzinga

IDEXX Laboratories Inc

IDXXNASDAQ

Trade with Public

Trade with Public

$509.38

-5.77-1.12%

Last update: Sep 10, 3:14 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

IDEXX Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for IDEXX Laboratories (IDXX).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

7Buy

4Hold

Consensus RatingOverweight# Analysts11Avg. Consensus PT$675Upside to Avg. PT+32.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 11, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$800→$710
Aug 5, 2026	UBS	Andrea Alfonso	PT Raise	Neutral	$620→$670
Aug 5, 2026	Citigroup	Daniel Grosslight	PT Raise	Neutral	$650→$670
Jul 27, 2026	UBS	Andrea Alfonso	PT Cut	Neutral	$640→$620
Apr 28, 2026	UBS	Andrea Alfonso	PT Cut	Neutral	$730→$640
Apr 15, 2026	Citigroup	Daniel Grosslight	Initiate	Neutral	$650
Mar 31, 2026	Stifel	Jonathan Block	PT Cut	Buy	$775→$675
Feb 9, 2026	Piper Sandler	David Westenberg	PT Cut	Neutral	$775→$750
Feb 5, 2026	Barclays	Glen Santangelo	PT Cut	Overweight	$850→$800
Feb 3, 2026	UBS	Andrea Alfonso	PT Cut	Neutral	$750→$730
Feb 3, 2026	BTIG	Mark Massaro	PT Cut	Buy	$830→$800
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$850
Nov 4, 2025	Morgan Stanley	Erin Wright	PT Raise	Overweight	$765→$805
Nov 4, 2025	UBS	Andrea Alfonso	PT Raise	Neutral	$710→$750
Nov 4, 2025	JP Morgan	Chris Schott	PT Raise	Overweight	$675→$775
Nov 4, 2025	BTIG	Mark Massaro	PT Raise	Buy	$785→$830
Oct 31, 2025	Stifel	Jonathan Block	Upgrade	Hold→Buy	$640→$700
Oct 1, 2025	UBS	Andrea Alfonso	Initiate	Neutral	$720
Aug 15, 2025	Morgan Stanley	Erin Wright	PT Raise	Overweight	$722→$765
Aug 11, 2025	Piper Sandler	David Westenberg	PT Raise	Neutral	$510→$700

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710

Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.

Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.

Benzinga Newsdesk

Why Is IDEXX Laboratories Stock Gaining Tuesday?

IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.

Vandana Singh

PRO
UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620

UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $640

UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $730 to $640.

Benzinga Newsdesk